There are no parenteral antihelminthic drugs licensed for use in humans. We report the successful treatment of disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin in a patient presenting with severe malabsorption and paralytic ileus. To our knowledge, ivermectin levels are reported for the first time in this situation.
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Strongyloides stercoralis infection affects 50-100 million people worldwide [1] . Initially acquired by percutaneous penetration of filariform larvae present in infested soil, this nematode perpetuates itself through autoinfection cycles [2] . It usually causes no or minor gastrointestinal and respiratory symptoms in travelers to and residents of areas where it is endemic [3] , but on occasion it is associated with multiorgan dissemination and a high mortality in patients infected with human T cell lymphotropic virus type 1 (HTLV1) and in patients who receive corticosteroids, chemotherapy, or transplants [2, [4] [5] [6] .
Oral administration of ivermectin is the preferred treatment for strongyloidiasis in immunocompetent [7] and immunocompromised humans [2, 8] . However, patients with severe strongyloidiasis frequently present with paralytic ileus [2, 5, 6, 9, 10] that precludes oral administration of ivermectin when it is urgently needed. No parenteral antihelminthic drugs are licensed for use in humans, but parenteral ivermectin is commonly used in veterinary medicine. We describe a patient who had disseminated strongyloidiasis that was successfully treated with a parenteral veterinary formulation of ivermectin. esophagitis, which was proven by biopsy. Dexamethasone therapy was discontinued.
Findings Methods. Given the worsening respiratory status, clinical malabsorption, and persistent ileus despite oral administration of ivermectin treatment, we contacted the Human Research Committee at our institution and the US Food and Drug Administration for emergency administration of parenteral ivermectin (Ivomec 1% injection; Merial Limited; New Animal Drug Application [NADA] 128-409). Permission was granted under the Investigational New Drug (IND) 69,582 for the subcutaneous administration of a 200-mg/kg dose. To minimize the risk of drug-related toxicity, additional doses were permitted if administered at least 48 h apart in response to persistent viable filariform larvae in induced sputum samples and nonresolution of the ileus, independent of the findings for stool samples. The patient gave written informed consent to proceed with the treatment and to measure plasma ivermectin levels.
Daily wet mounts of stool and sputum were used initially for monitoring. When the parasite burden decreased, stool specimens were concentrated using the formalin-ethyl-acetate sedimentation technique. Sputum sample pellets were examined after digestion with dithiothreitol, which did not compromise the parasite's viability.
Sequential plasma samples were obtained and stored at Ϫ80ЊC until processing. Ivermectin was analyzed by high-performance liquid chromatography by means of a modified assay [12] .
Results and clinical course. The patient received ivermectin solution (200 mg/kg) administered subcutaneously on 17 June, 19 June, and 22 June 2004 in both upper arms because of significant dependent edema. The drug regimen, ivermectin levels, and antiparasitic effects are summarized in figure 2 .
The patient experienced no local or systemic reactions. He received vancomycin therapy for catheter-related methicillinresistant Staphylococcus aureus bacteremia and received acyclovir therapy for a herpes simplex virus type 2 outbreak. He experienced prolonged intermittent fevers without other identifiable etiology. Investigations included blood cultures, tests for cytomegalovirus and other viruses, CT of head and ab- Figure 2 . Ivermectin levels and Strongyloides stercoralis burden in relation to method of administration. The upper 2 panels are a semiquantitative representation of the parasite burden in sputum and stool samples. The relative abundance of rhabditiform and filariform larvae, adults, and eggs were taken into account for the measurement. Larvae were considered nonviable if they were completely immobile or degenerating. The ivermectin level before the initial subcutaneous administration and after cumulative doses of oral ivermectin (total dosage, 1000 mg/kg over 3 days) was only 1.1 ng/mL. The ivermectin levels after the first subcutaneous dose were between 2.0 and 4.2 ng/mL. The level at 1 week after the third subcutaneous dose was 7.9 ng/mL, with evidence of additional metabolite accumulation. Individual doses are represented by arrows; additional subcutaneous doses were administered in response to the presence of viable filariform larvae in sputum samples, independent of findings for stool samples.
domen, and gallium scan. A pulmonary embolism protocol CT revealed deep venous thrombosis involving the right femoral veins, for which the patient received enoxaparin therapy.
The albumin level remained at !1.5 g/dL, despite the resolution of diarrhea and the patient's increased appetite. The patient developed thrombocytopenia prior to receiving ivermectin therapy, with a platelet count nadir of 47,000 platelets/ The results of monthly stool samples have remained negative. The patient has received 2-day courses of oral ivermectin during each cycle of chemotherapy [2] .
Discussion. For patients with disseminated strongyloidiasis who are unable to ingest or absorb oral medication, there is no parenteral antihelminthic therapy licensed for human use. Tarr et al. [14] described a patient with ileus whose condition was successfully treated with simultaneous oral and rectal administration of ivermectin and oral administration of albendazole. Rectal drug administration was unlikely to be effective in our patient, given the concurrent diarrhea and abundant S. stercoralis adults and eggs seen in stool specimens, which suggested significant colonic involvement [2, 5] . Chiodini et al. [15] used subcutaneously administered ivermectin for 2 pa-tients; the infection was controlled in 1 patient, and strongyloidiasis was not confirmed in the other patient, but no details were provided.
The administration of parenteral ivermectin licensed for veterinary use-and available in the United States and other countries-was safe and effective in treating disseminated strongyloidiasis in our patient. For the first time in this situation, we documented ivermectin levels, which were below the average of those reported in normal subjects after oral administration (peak plasma concentration ‫ע[‬ SD], 48.5 ‫ע‬ 35.2 ng/mL) [16] . Ivermectin is highly bound to serum albumin [17] ; thus, severe hypoalbuminemia may have contributed to a slower absorption from tissue edema, a larger volume of distribution, and an increased clearance of unbound drug. There was an accumulation of ivermectin and its metabolites after repeated doses and a sustained antiparasitic effect. No minimally effective ivermectin concentrations have been established for the treatment of strongyloidiasis in humans [16] , but 2.4 ng/mL of ivermectin was required to paralyze 50% of Strongyloides ratti and Strongyloides venezuelensis filariform larvae in vitro [18] . Persistent fevers after treatment may have been in part a consequence of the host response to dying disseminated larvae after discontinuation of corticosteroid therapy. We did not prove relapse or CNS dissemination at readmission, but additional ivermectin was prescribed, given the patient's multiple risk factors for relapse [2] .
The best strategy for preventing S. stercoralis hyperinfection and related death is to identify and treat chronically infected patients prior to initiation of immunosuppressive therapy [1, 2] . Specific antibody detection [3, 13] and serial stool sampling with special methods [2] are currently the best diagnostic strategies. The importance of preventive measures, including wearing appropriate footwear, should be communicated to patients living in or traveling to areas where S. stercoralis is endemic. Our patient likely acquired the infection recently, because he had previously tolerated steroid-containing chemotherapy despite having chronic HTLV1 infection. A search for this parasite is warranted for immunocompromised patients who present with diarrhea, respiratory syndromes, unexplained bacteremia or meningitis with gastrointestinal flora, malabsorption, or ileus [2, 3, 5] .
In this case, the use of subcutaneous ivermectin and the preemptive use of antimicrobials [19] prevented further complications associated with disseminated strongyloidiasis and were lifesaving. Studies with parenteral ivermectin for licensing of use in humans are warranted. Meanwhile, clinicians faced with a patient who has severe strongyloidiasis and concurrent ileus or significant malabsorption should consider early treatment with subcutaneous ivermectin.
